These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 28420721)

  • 1. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
    Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
    Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
    Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
    Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
    Li T; Christensen SD; Frankel PH; Margolin KA; Agarwala SS; Luu T; Mack PC; Lara PN; Gandara DR
    Invest New Drugs; 2012 Apr; 30(2):741-8. PubMed ID: 20967484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
    Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A
    Br J Cancer; 2024 Mar; 130(5):788-797. PubMed ID: 38200233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.
    Caimi PF; Cooper BW; William BM; Dowlati A; Barr PM; Fu P; Pink J; Xu Y; Lazarus HM; de Lima M; Gerson SL
    Oncotarget; 2017 Oct; 8(45):79864-79875. PubMed ID: 29108368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
    Cooper JP; Reynolds CP; Cho H; Kang MH
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
    Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
    Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative carbohydrate load and intraoperatively infused omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary artery bypass grafting: a double-blind controlled randomized trial.
    Feguri GR; de Lima PRL; de Cerqueira Borges D; Toledo LR; Batista LN; E Silva TC; Segri NJ; de Aguilar-Nascimento JE
    Nutr J; 2017 Apr; 16(1):24. PubMed ID: 28427403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.
    Kunos CA; Chu E; Makower D; Kaubisch A; Sznol M; Ivy SP
    Front Oncol; 2017; 7():62. PubMed ID: 28421163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.
    Alfei S; Zuccari G
    Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Biological Evaluations of Granulatamide B and its Structural Analogues.
    Matulja D; Grbčić P; Matijević G; Babić S; Bojanić K; Laclef S; Vrček V; Čož-Rakovac R; Pavelić SK; Marković D
    Curr Med Chem; 2024; 31(25):3997-4021. PubMed ID: 38347783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
    Boulter AC; Maurer BJ; Pogue M; Kang MH; Cho H; Knight A; Reynolds CP; Quick D; Awasthi S; Gerber DE
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):97-105. PubMed ID: 37199745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTCL, NOS: An update on classification, risk-stratification, and treatment.
    Weiss J; Reneau J; Wilcox RA
    Front Oncol; 2023; 13():1101441. PubMed ID: 36845711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma.
    Pomella S; Porrazzo A; Cassandri M; Camero S; Codenotti S; Milazzo L; Vulcano F; Barillari G; Cenci G; Marchese C; Fanzani A; Megiorni F; Rota R; Marampon F
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids and Lymphomas: A Double-Edged Sword.
    Pherez-Farah A; López-Sánchez RDC; Villela-Martínez LM; Ortiz-López R; Beltrán BE; Hernández-Hernández JA
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
    Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
    Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Sphingolipids for Cancer Therapy.
    Companioni O; Mir C; Garcia-Mayea Y; LLeonart ME
    Front Oncol; 2021; 11():745092. PubMed ID: 34737957
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.